SAMİLEH NOORBAKHSH, NAHİD RAHİMZADEH, ROZİTA HOSSEİNİ, HASAN OTOOKESH, FAHİMEH EHSANPOOR, YASAMAN AMİNPOUR
Experimental and Clinical Transplantation - 2022;20(7):663-667
Objectives: Calcineurin inhibitors (cyclosporine and tacrolimus) are widely used in kidney transplant to prevent acute transplant rejection; however, the effects of these medications on graft sequelae after transplant remain unclear. We aimed to compare early complications, including graft rejection and infection rates after kidney transplant, in children between the cyclosporine and tacrolimus immunomodulator regimens. Materials and Methods: In this prospective cohort study, 105 pediatric patients who were candidates to receive kidney transplant in the age range of 4 to 18 years were included. There were 28 patients who received cyclosporine, and 77 patients who received tacrolimus. Participants were routinely tested for cytomegalovirus, BK virus, and bacterial infection on a monthly basis for the first 3 months and once every 3 months thereafter for the first year. The graft rejection rate was also assessed and compared between the 2 treatment regimens. Results: There were no significant differences between the 2 groups receiving cyclosporine or tacrolimus in graft rejection rate (P = .719), cytomegalovirus viremia (P = .112), BK viremia (P = .278), and bacterial infection (P = .897). Graft failure was significantly more frequent in male than in female patients (30.9% vs 8.2%; P = .004). The rates of graft failure in study patients with and without previous history of graft failure were found to be statistically similar (16.7% vs 20.4%; P = .825). History of infection in donors did not affect the graft complications posttransplant in recipients. Conclusions: The use of either tacrolimus or cyclosporine leads to similar consequences in terms of graft rejection or posttransplant viral and bacterial infection, so either drug may be exchanged for the other if needed for tolerability.
